HydroVax-005 is under clinical development by Najit Technologies and currently in Phase I for Chikungunya Fever. According to GlobalData, Phase I drugs for Chikungunya Fever have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HydroVax-005’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HydroVax-005 overview
Vaccine candidate is under development for the prevention of Chikungunya infections. The vaccine candidate is an inactivated vaccine, developed based on Hydrovax technology. It is administered through intramuscular route.
Najit Technologies overview
Najit Technologies operates within the pharmaceuticals and healthcare industry, specifically focusing on the production of generic vaccines. It specializes in the manufacturing and distribution of generic vaccine products.
For a complete picture of HydroVax-005’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
